NASDAQ:ALPN Alpine Immune Sciences (ALPN) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$64.97▼$64.9750-Day Range$64.37▼$64.9752-Week Range$8.33▼$65.00Volume938 shsAverage Volume1.92 million shsMarket Capitalization$4.46 billionP/E RatioN/ADividend YieldN/APrice Target$52.33 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Alpine Immune Sciences alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Alpine Immune Sciences Stock (NASDAQ:ALPN)Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. ALPN Stock News HeadlinesMay 16, 2024 | markets.businessinsider.comWhat 11 Analyst Ratings Have To Say About Alpine Immune SciencesMay 10, 2024 | investorplace.comALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q1 2024July 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 9, 2024 | businesswire.comAlpine Immune Sciences Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comVertex Pharmaceuticals Inc (VRTX) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...May 1, 2024 | morningstar.comAlpine Immune Sciences IncApril 27, 2024 | benzinga.comLatest News for Alpine Immune Sciences Stock (NASDAQ:ALPN)April 27, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune ...July 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! April 26, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPNApril 23, 2024 | finance.yahoo.comAlpine Immune Sciences, Inc. (ALPN)April 18, 2024 | msn.comTD Cowen Downgrades Alpine Immune Sciences (ALPN)April 17, 2024 | prnewswire.comINVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPNApril 17, 2024 | msn.comAlpine Immune Sciences (ALPN) Price Target Increased by 36.91% to 63.24April 15, 2024 | investorplace.comCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?April 13, 2024 | fool.comCould This Stock Be the Next Biotech Buyout?April 12, 2024 | stockhouse.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Alpine Immune Sciences, Inc. BuyoutApril 12, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPNSee More Headlines Receive ALPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALPN CUSIPN/A CIK1626199 Webwww.alpineimmunesciences.com Phone(206) 788-4545Fax303-440-8399Employees142Year FoundedN/APrice Target and Rating Average Stock Price Target$52.33 High Stock Price Target$65.00 Low Stock Price Target$18.00 Potential Upside/Downside-19.5%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,180,000.00 Net Margins-65.17% Pretax Margin-64.99% Return on Equity-14.86% Return on Assets-11.82% Debt Debt-to-Equity RatioN/A Current Ratio9.56 Quick Ratio9.56 Sales & Book Value Annual Sales$56.52 million Price / Sales78.85 Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book13.40Miscellaneous Outstanding Shares68,598,000Free Float39,581,000Market Cap$4.46 billion OptionableOptionable Beta0.97 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Mitchell H. Gold M.D. (Age 56)Executive Chairman & CEO Comp: $778.2kDr. Stanford Peng M.D. (Age 53)Ph.D., President and Head of Research & Development Comp: $751.2kMr. Paul Rickey (Age 45)Senior VP, CFO, Treasurer & Secretary Comp: $577.1kMs. M. Christina Yi (Age 47)Chief Technology Officer Temre JohnsonHead of IR & Corporate CommunicationsDr. Remy Durand Ph.D. (Age 39)Chief Business Officer Dr. Wolfgang Dummer M.D. (Age 58)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsFive Prime TherapeuticsNASDAQ:FPRXXencorNASDAQ:XNCRZymeworksNYSE:ZYMEHarpoon TherapeuticsNASDAQ:HARPMacroGenicsNASDAQ:MGNXView All CompetitorsInsiders & InstitutionsLynx1 Capital Management LPSold 1,560,743 shares on 5/30/2024Ownership: 3.285%Boston PartnersBought 23,101 shares on 5/28/2024Ownership: 0.034%Farallon Capital Management LLCBought 5,900 shares on 5/24/2024Ownership: 0.009%Virtu Financial LLCBought 14,813 shares on 5/20/2024Ownership: 0.022%Artal Group S.A.Bought 355,025 shares on 5/17/2024Ownership: 0.592%View All Insider TransactionsView All Institutional Transactions ALPN Stock Analysis - Frequently Asked Questions How were Alpine Immune Sciences' earnings last quarter? Alpine Immune Sciences, Inc. (NASDAQ:ALPN) posted its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.15. The biotechnology company earned $7.03 million during the quarter, compared to the consensus estimate of $5.50 million. Alpine Immune Sciences had a negative net margin of 65.17% and a negative trailing twelve-month return on equity of 14.86%. What other stocks do shareholders of Alpine Immune Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA) and OPKO Health (OPK). This page (NASDAQ:ALPN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpine Immune Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alpine Immune Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
